Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) on Behalf of Investors

Fulcrum Therapeutics discontinued its pociredir program for sickle cell disease after FDA concerns that PRC2-targeting therapies carry a malignancy risk, concluding there is no viable regulatory path forward. The stock fell from $6.42 on June 1, 2026 to $3.14 on June 2, 2026 (down $3.28, or -51.09%). Separately, Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, adding legal overhang for investors.

Analysis

This is less a litigation story than a terminal-value reset. Once a small-cap clinical asset loses regulatory credibility, the equity trades like a cash runway option, so the next incremental driver is financing terms rather than legal discovery. That means the biggest near-term loser is not just the stockholder base but any future capital provider: every missed quarter raises the dilution burden and compresses the valuation multiple on any remaining pipeline.

The second-order effect is on the broader small-cap biotech tape. Names with a single-asset, rare-disease or immunology binary readout can see sympathy pressure because investors use one failure to reprice probability-of-success assumptions across the basket, but that spillover is usually brief unless another company has the same mechanistic exposure. Larger diversified peers should not trade on this; the read-through is more about capital markets access than science.

The contrarian point is that the headline damage may already be mostly in the tape after the initial gap down. If the company’s cash balance is still adequate and no dilutive financing is imminent, chasing the short after a 50% reset risks poor asymmetry; the better trigger is a relief rally into thin liquidity or a new filing that quantifies runway. What would falsify the bearish thesis is a clear extension of cash runway beyond the next 12 months, a non-dilutive partnership, or evidence that management can materially cut burn without another raise.

Key Decisions for Investors

• Short FULC on any 1-2 week relief bounce rather than into the open; use a tight stop above the post-event breakdown zone and target a re-test of lows if financing risk surfaces.
• If options liquidity is usable, buy a 1-3 month FULC put spread to express downside while capping premium decay; the catalyst is runway disclosure or a financing announcement, not litigation headlines.
• Pair trade: short FULC versus long XBI to isolate idiosyncratic regulatory/capital-raise risk while hedging market beta; this is cleaner than a naked biotech short.
• Set an alert for the next 10-Q, cash burn, and any ATM/PIPE language; if runway is under 12 months or a raise is announced, add to the short, but cover if management shows materially extended runway or a non-dilutive deal.